Astria Therapeutics, Inc.
Astria Therapeutics, Inc. (ATXS): 5 pipeline candidates · ~21 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.3 months
D/E 0.17 · 3% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for Astria Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$718.1M
Cash
$96.3M
Quarterly Burn
$32.3M
Runway
21.3 mo
Revenue
$706K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| navenibart | Phase 3 |
| navenibart (formerly STAR-0215) | Phase 3 |
| STAR-0215 | Phase 1/Phase 2 |
| STAR-0310 | Phase 1 |
| vial | Phase 1 |
Frequently asked questions
How many drug candidates are in Astria Therapeutics, Inc.'s pipeline?
Astria Therapeutics, Inc. (ATXS) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Astria Therapeutics, Inc.'s lead drug candidate?
Astria Therapeutics, Inc.'s most advanced tracked candidate is navenibart (Phase 3) for Hereditary Angioedema (HAE).
What is Astria Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Astria Therapeutics, Inc. has approximately 21.3 months of cash runway.
What is Astria Therapeutics, Inc.'s market capitalization?
Astria Therapeutics, Inc.'s market capitalization is approximately $718.1M.
Who is the CEO of Astria Therapeutics, Inc.?
Chief Executive Officer is the chief executive officer of Astria Therapeutics, Inc. (ATXS).
Get the full picture on Astria Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.